For those of you running a US/UK FTA, there are still disagreements concerning pharmaceuticals, but an agreement is getting close, but not till 2024. This article in Endpoint News will explain. This issue in a nutshell is that with Brexit, the UK was no longer part of the EU system of drug approval, which was the EMA giving a recommendation and the EC giving final approval.
After Brexit, the MHRA became the approval mechanism for the UK. However, there is currently no reciprocal drug approval between the FDA of the US and the MHRA of the UK. Therefore, signing a full FTA would have some problems in this arena. If this is your AFF, you may want to change the mandate to everything but Pharmaceuticals, and add them when a reciprocal aggreement is reached.
